Another promising target described in the MS literature and enhanced at 25 dpi might be a suppressor of cytokine signaling 3 (SOCS3), an inhibitor of JAK/STAT and leptin pathways in microglia, which could reduce the toxic inflammatory response during relapse — probably by regulating IL-6 (29, 30). Here, SOAT1 is linked to myeloid sarcoma.